The Sensex will see 62111 closing above 61444 in the new week

(Gujarat News Correspondent) Mumbai; The Sensex and Nifty-based overbought positions in Indian stock markets have eased over the past week and small, mid-cap stocks have been in a slump. The stocks have been waiting for a correction for a long time after witnessing a long-term bullish-baroque indiscriminate storm. But each time, the funds have tightened their grip on the stock market, raising the bar of speculation by misleading many and bringing stock prices to extraordinary heights. With this, the Sensex crossed the 9000 level and the Nifty crossed the 1700 level, creating a new history. This level has finally undergone a major correction in the last week after the experts, who have been fighting the battle of stubbornness to feed the players of the recession and recession that have become inevitable at this level, have fed many. NSE Leverage in mid-cap stocks, too, has taken a toll on margins by plunging stocks into losses. With Nifty-based recession victims forced to do short covering, funds are now grabbing good stocks in small, mid-cap stocks as well. The market is likely to rebound next week amid the possibility of a reversal. At the beginning of this new wave of growth, don't be surprised if the market gap opens on the positive impact of the 5% surge in fantastic net profit for the second quarter ended September 2021, Reliance Industries, announced on Friday. It will be possible to see 2111 when it closes.

Dark Horse: Sanofi India Ltd.

BSE (2008), NSE (SANOFI), Listed Rs. 10 paid-up, 1: 1 share bonus issue in the year 18, holding 2.50% bonus equity in total equity SANOFI INDIA LTD.) The company, which has been in India for 15 to 20 years and has more than 4,000 employees, specializes in various segments in the healthcare sector including Diabetes and Cardiovascular Solutions, Central Nervous System, Infectious Diseases, Infectious Diseases, Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Active in the field of consumer healthcare. The company has three manufacturing facilities and one development center in Goa and Hyderabad. More than 50 countries receive the company's finished formulations, active pharmaceutical ingredients (APIs), medical devices and vaccines. The Sanofi Group, which operates in 100 countries, provides healthcare solutions in more than 150 countries worldwide and is one of the world's leading reputable companies. Sanofi Pasteur's inactivated polio vaccine has been given to every second child in India. Sanofi India produces 10 billion tablets annually and meets 5% of domestic demand with locally produced products.

Nutraceuticals business transfer revenue of Rs. 3 crore:

Sanofi India Limited has transferred its nutraceuticals business to Universe NutraScience Pvt Ltd for Rs 2 crore, including liabilities. If the conditions are met as per the agreement, the company has received Rs 4.5 crore on the closing date of September 30, 2021.

Cash reserves:

Sanofi India has a cash reserve of Rs 114 crore, valued at Rs 50 per share. In addition, Sanofi India has given a loan of Rs 20 crore to Sanofi France on a corporate guarantee, valued at Rs 500 per share.

Share holding pattern:

Promoters Hackst GmbH has 70.5 per cent and Sanofi has 0.05 per cent, promoters have 30.50 per cent, mutual funds have 11.5 per cent, Aditya Birla Sun Life Trustee has 7.5 per cent and UTI-Mastershare Unit Scheme has 1 per cent. Nippon Life India Trustee has 2.18 per cent, ICICI Prudential Pharma Fund has 1.4 per cent. Foreign Portfolio Investors (FPIs) have 10.3 per cent, Insurance Companies have 2.15 per cent, Life Insurance Corporation of India has 2.50 per cent, HDFC Life Insurance Company has 1.15 per cent and Bajaj Alliance Lines has 1 per cent. Is. Corporate bodies have 4.5 per cent. While individual share capital holders with up to Rs 3 lakh have 2.31 per cent.

Book value:

Rs. 206.31 in December 2016, Rs. 3.5 in December 2016, Rs. 4.5 in December 2016, Rs. 3.5 in December 2016, Rs. 2021 is Rs. Sanofi India, on the other hand, has a cash reserve of Rs 114 crore, valued at Rs 50 per share. In addition, Sanofi India has given a loan of Rs 20 crore to Sanofi France on a corporate guarantee, valued at Rs 500 per share.

Dividends:

20% in 2014, 210% in 2014, 30% in 2014, 500% in 2020 (with special dividend), 200% in 2021 and 150% with final 20%.

Financial results:

Sanofi India Ltd. having a financial year from January to December

(1) Full year January 2020 to December 2020:

Net profit fell to Rs 301.50 crore from Rs 5,050.50 crore, net profit margin increased by 12.5 per cent to Rs 515.50 crore, up 17.50 per cent to Rs 2.50 crore. EPS rose from Rs 12.5 to Rs 303.5.

(2) Second Quarter March 2021 to June 2021:

Net profit rises to Rs 2.10 crore from Rs 310.50 crore, net profit margin-NPM rises to Rs 19.70 crore from 6.15 per cent Income has increased from Rs 2.15 to Rs 4.5.

(2) First Half Yearly January 2021 to June 2021:

Net profit rises to Rs 1,412.50 crore from Rs 15 crore Net profit margin-NPM net profit rises to Rs 2.50 crore from 20.51 per cent net profit rises to Rs 2.50 crore Achieved Rs.150.5 from Rs.5.5.

(2) Expected full year January 2021 to December 2021:

The full-year earnings per share is expected to be Rs 2.31, with a net profit of Rs 5 crore out of the expected net income of Rs 2.5 crore.

(2) Valuation: M:

P / E of Abbott India 3.50, P / E of AstraZeneca Pharma 2.50, Glaxo Pharma 3.10, Novartis India 3 and P&G Health Ltd. against the average P / E of 30 in the pharmaceuticals industry. P / EA of 3.50 is available, while Sanofi India Limited has a P / EA of only 4.5 against the expected earnings.

Thus, (1) Foreign Promoter Hackst GmbH has 20.8% and Sanofapas has 0.05% together and the promoters have 30.50% (2) Bonus equity of 2.50% in total equity. (3) First half year (2) Expected full year January to December with a cash reserve of Rs. The stock is currently available at NSE, BSE with a P / EA of Rs 4.5 against the expected earnings per share of Rs 4.51 in 2021 and the expected book value of Rs 1913.5.

Dark Horse Recommendation Review-Modification: LIC Housing Finance Single B to Hold-H

Among the recommendations of Scripps made here as Dark Horse, LIC Housing Finance Ltd. is now being placed on hold-H, replacing Single B. The stock has a closing price of Rs.

Manoj Shah: Research Analyst (SEBI REG. NO. INH000000107)

The author is a SEBI registered research analyst: Disclosure cum (readers should take special note) Warning: (1) The author has no investment in the shares of the above companies. (3) Our resources for researchers may be of direct or indirect interest, such as broking houses, promoter views, personal research analysts, portfolio management or their team. (3) Maintaining a 30% stop loss from the Reachers price, in particular, is advice and warning. (2) Valuation H, B, BB, BBB Top Gainers These are all possibilities, so don't invest temptingly. (2) Generally, out of every 10 scrips, 4 scrips are true and 4-5 scrips are false. This type of research is excellent. (3) Feedback E-mail: All the above points also apply to the answers given in arjuneyems@gmail.com. (2) The reader class, the investor class to take their own personal decisions at personal risk. The writer, editor and anyone of Gujarat Samachar will not be responsible for your loss. So invest by recognizing the risk of the stock market.